Its prevalence in the United States is approximately 41.9% of adults (CDC, 2024), making it one of the most frequently encountered diagnoses in inpatient, outpatient, and value-based care settings
AHA Coding Clinic (Recent Guidance) The following represents coding guidance and principles from AHA Coding Clinic relevant to obesity and BMI coding
For obesity alone, coverage follows the same optional state rules as Wegovy 13 states cover it as of early 2026
Every state Medicaid program covers GLP-1s for Type 2 diabetes
All suspected adverse reactions to Mounjaro should be reported, especially: Serious reactions, regardless of whether they are well-recognised Reactions resulting in hospitalisation or prolonged hospitalisation Suspected reactions causing congenital abnormalities Any reaction not previously documented in the Summary of Product Characteristics Reports can be submitted online at www.mhra.gov.uk/yellowcard , via the Yellow Card app, or by telephone